Pasar al contenido principal

TERAPIA MOLECULAR DE LA HIPEROXALURIA PRIMARIA

BES-2012-052719

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Nacional de Formación de Personal Investigador
Subprograma Subprograma de Ayudas de Formación de Personal Investigador
Convocatoria Contratos Predoctorales
Año convocatoria 2012
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario FUNDACION CANARIA RAFAEL CLAVIJO PARA LA INVESTIGACION BIOMEDICA
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Salicylic Acid Derivatives Inhibit Oxalate Production in Mouse Hepatocytes with Primary Hyperoxaluria Type 1

  • Moya-Garzón, María Dolores
  • Martín Higueras, Cristina
  • Peñalver, Pablo
  • Romera, Manuela
  • Fernandes, Miguel X.
  • Franco-Montalbán, Francisco
  • Gómez-Vidal, José A
  • Salido, Eduardo
  • Díaz-Gavilán, Mónica
Primary hyperoxaluria type 1 (PH1) is a rare life-threatening genetic disease related to glyoxylate metabolism and characterized by accumulation of calcium oxalate crystals. Current therapies involve hepatic and/or renal transplantation, procedures that have significant morbidity and mortality and require long-term immunosuppression. Thus, a pharmacological treatment is urgently needed. We introduce here an unprecedented activity of salicylic acid derivatives as agents capable of decreasing oxalate output in hyperoxaluric hepatocytes at the low micromolar range, which means a potential use in the treatment of PH1. Though correlation of this phenotypic activity with glycolate oxidase (GO) inhibition is still to be verified, most of the salicylic acids described here are GO inhibitors with IC50 values down to 3 μM. Binding mode of salicylic acids inside GO has been studied using in silico methods, and preliminary structure-activity relationships have been established. The drug-like structure and ease of synthesis of our compounds make them promising hits for structural optimization., We acknowledge the Oxalosis and Hyperoxaluria Foundation(OHF) for supporting this investigation through a Research Grant to our team (OHF Research Grant Program 2013, IPM.D.-G.). We thank the Spanish Ministry of Economy for apredoctoral FPI fellowship to C.M.H. (Grant BES-2012-052719) and a research project to E.S. (Grant SAF2015-69796), and the University of Granada for a predoctoral FPUfellowship to M.D.M.-G and a research grant to M.D.-G. (GrantPP2016-PIP05)., Peer reviewed